Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Calcifying pseudoneoplasm of the neuraxis progressing to G5/PDGFRA subgroup glioblastoma in a United States Army veteran with a history of head trauma and germline POT1 and EPHB2 mutations: illustrative case.
Georgescu MM et al.
Journal of Neurosurgery. Case Lessons, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Lucas CG et al.
Neuro-oncology, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.
Andrade AF et al.
Nature Communications, 2024
PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling.
de Villenfagne L et al.
Scientific Reports, 2024
Molecular and clonal evolution in vivo reveal a common pathway of distant relapse gliomas.
Liu G et al.
Iscience, 2023
On a mechanistic impact of transmembrane tetramerization in the pathological activation of RTKs.
Polyansky AA et al.
Computational and Structural Biotechnology Journal, 2023
Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid.
Sheng Z et al.
Frontiers in Oncology, 2023
Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
Higa N et al.
Neurologia Medico-chirurgica, 2022
Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma.
DeSisto J et al.
Nature Communications, 2021
Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications.
Georgescu MM
Cancers, 2021
PDGF receptor mutations in human diseases.
Guérit E et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Application of Cluster Analysis of Time Evolution for Magnetic Resonance Imaging -Derived Oxygen Extraction Fraction Mapping: A Promising Strategy for the Genetic Profile Prediction and Grading of Glioma.
Shen N et al.
Frontiers in Neuroscience, 2021
Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study.
Nørøxe DS et al.
Molecular Oncology, 2020
Mislocalisation of Activated Receptor Tyrosine Kinases - Challenges for Cancer Therapy.
Schmidt-Arras D et al.
Trends in Molecular Medicine, 2020
Atomistic mechanism of the constitutive activation of PDGFRA via its transmembrane domain.
Polyansky AA et al.
Biochimica Et Biophysica Acta. General Subjects, 2019
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.
Ip CKM et al.
Nature Communications, 2018
Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors.
Koschmann C et al.
Jco Precision Oncology, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Longitudinal analysis of treatment-induced genomic alterations in gliomas.
Erson-Omay EZ et al.
Genome Medicine, 2017
Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling.
Arts FA et al.
Journal of Cellular and Molecular Medicine, 2015
Point mutations in dimerization motifs of the transmembrane domain stabilize active or inactive state of the EphA2 receptor tyrosine kinase.
Sharonov GV et al.
The Journal of Biological Chemistry, 2014
PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.
Velghe AI et al.
Oncogene, 2014
CanDrA: cancer-specific driver missense mutation annotation with optimized features.
Mao Y et al.
Plos One, 2013
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Elling C et al.
Blood, 2011
Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.
Nasrallah MP et al.
Academic Pathology, 0